



## The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

## 732.ALLOGENEIC TRANSPLANTATION: DISEASE RESPONSE AND COMPARATIVE TREATMENT STUDIES

**Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience**

Derya Koyun<sup>1</sup>, Uğur Şahin<sup>2</sup>, Güldane Cengiz Seval<sup>1</sup>, Deniz Gören Şahin<sup>3</sup>, Ayla Gökmen<sup>2</sup>, Sinem Civriz Bozdağ<sup>1</sup>, Selami Kocak Toprak<sup>1</sup>, Pervin Topçuoğlu<sup>1</sup>, Meltem Kurt Yüksel<sup>1</sup>, Önder Arslan<sup>1</sup>, Taner Demirel<sup>1</sup>, Günhan Gürman<sup>1</sup>, Osman İlhan<sup>1</sup>, Meral Beksac, MD<sup>1</sup>, Muhit Özcan<sup>1</sup>, Mutlu Arat<sup>3</sup>

<sup>1</sup> Ankara University School of Medicine, Hematology Department, Ankara, Turkey

<sup>2</sup> Medicana International Ankara Hospital, Hematology Department, Ankara, Turkey

<sup>3</sup> İstanbul Florence Nightingale Hospital, Hematology Department, İstanbul, Turkey

**Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience****Introduction**

Relapsed and/or refractory (R/R) Hodgkin Lymphoma (HL) after autologous stem cell transplant (SCT) is associated with poor outcomes and nearly 50% of patients will ultimately relapse. Novel therapeutic agents such as checkpoint inhibitors (CPIs) (nivolumab, pembrolizumab) and brentuximab vedotin (BV) have both shown considerable activity in this patient population, but allogeneic SCT (alloSCT) maintains its curative potential also in the era of new drugs. Herein we report on our multicenter experience with alloSCT for R/R HL.

**Methods**

Seventy patients with R/R classic HL who underwent alloSCT between 2004 and 2021 in three transplant centers were included. Patients were included between 2004-2010 (era1) in one centre, 2011-2021 (era2) in all centers. Disease response was evaluated according to Lugano classification. Primary end point was post transplant (tx) overall response rate (ORR). Secondary endpoints were overall survival (OS), progression free survival (PFS), non relapse mortality (NRM) and response rates according to parameters especially tx years, and pre/post tx CPIs and/or BV usage.

**Results**

Patient characteristics are summarized in the Table. Median follow up time after alloSCT was 64 months (range, 40.7-87.3). Post tx disease relapse or progression occurred in 23 patients (33%). The median time to disease relapse was 6.3 months (range, 1-24.5). Twenty nine patients were alive at the analytic date (41%); 23 in complete response (CR) (79%), 4 partial response (PR) (14%), 2 stable disease (SD) (7%). The 3-year OS, PFS were 39% (95% CI 27.2-50.8) and 28% (95% CI 16.2-39.8), respectively; the day 100 and 1-year NRM rates were 26% (95% CI 16.2-35.8) and 37% (95% CI 25.2- 48.8), respectively.

According to the tx year, the pre tx response rates were not statistically different between the two eras ( $p=0.46$ ) but post tx CR rates were significantly higher in era2 ( $p=0.01$ ). The survival (OS, PFS) analysis and NRM rates demonstrated no difference between both eras, but the PFS was significantly longer in 2016 and after ( $p=0.03$ ). Patients who received alloSCT between era 1 and era 2 in one and only centre; the survival rates, and NRM were similar across the two eras.

The patients with chemosensitive disease (CR, PR) at the time of alloSCT had more common pre tx BV usage ( $p=0.03$ ), RIC conditioning regimen ( $p=0.002$ ), and were with high HCT CI score ( $p=0.02$ ), while the low proportion of ATG usage ( $p=0.02$ ). Achievement of a CR at pre tx associated with better OS, PFS, and NRM. Patients in CR at the time of the post tx was associated with significantly improved OS and PFS ( $p<0.05$ ).

Patients who received BV and CPIs at any point pre and post tx had better OS, PFS and the NRM was low, but not statistically significant. There was a lower NRM rates in the post tx BV ( $p=0.06$ ) and CPIs ( $p=0.08$ ) usage.

Regarding to post tx cyclophosphamide (cy) versus ATG usage; patients who received ATG had significantly shorter OS ( $p=0.04$ ), an increase in NRM ( $p=0.01$ ), but similar PFS ( $p=0.28$ ) compared with those who did not. Patients who received post tx cy had significantly better OS ( $p=0.04$ ) and PFS ( $p=0.05$ ) but similar NRM ( $p=0.19$ ) compared with those who did not. There was no statistically significant difference in OS, PFS and NRM with regard to the conditioning regimens (RIC and MAC) ( $p>0.05$ ).

Regarding donor type; the use of pre tx CPIs, TBI in conditioning regimen, and post cy were common for haploidentical (haplo) tx ( $p < 0.05$ ). ATG was used more commonly for matched/mismatched unrelated donor (MUD/MMUD) when compared with matched related donor (MRD) ( $p < 0.001$ ). The incidence of acute graft versus host disease (GVHD) ( $p = 0.09$ ) and chronic GVHD ( $p = 0.002$ ) were higher in patients who received MRD grafts when compared with MUD/MMUD and haplo. Haplo donors had significant better OS ( $p = 0.015$ ) and PFS ( $p = 0.03$ ) compared with MUD/MMUD and MRD. There was a significantly higher NRM in the MUD/MMUD compared with others ( $p < 0.05$ ).

### Conclusions

Our results suggest that alloSCT continues to play an important therapeutic role for patients with R/R cHL. The improved outcomes of alloSCT in HL over time, probably due to general improvements in supportive care, a better selection of patients and the arrival of novel therapeutic therapies. The efficacy of alloSCT can be determined by multicenter prospective studies in selected patient groups.

**Disclosures Beksac:** *Takeda*: Speakers Bureau; *Sanofi*: Speakers Bureau; *Menarini*: Membership on an entity's Board of Directors or advisory committees; *BMS*: Speakers Bureau; *Janssen*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

<https://doi.org/10.1182/blood-2023-182741>




Figure. (A) Overall, (B) progression free survival, after alloSCT

Figure 1

Table. Patients' characteristics

|                       |          |                  |       |
|-----------------------|----------|------------------|-------|
| Center                | Center1  | 28               | 40.0% |
|                       | Center2  | 27               | 38.6% |
|                       | Center3  | 15               | 21.4% |
| Tx-year               | Era 1    | 16               | 22.9% |
|                       | Era 2    | 54               | 77.1% |
| Age                   |          | 35 (18-62)       |       |
| Follow-up time, month |          | 64.0 (40.7-87.3) |       |
| Age                   | ≤40      | 49               | 70.0% |
|                       | >40      | 21               | 30.0% |
| Sex                   | Male     | 41               | 58.6% |
|                       | Female   | 29               | 41.4% |
| PrealloSCT HCT-CI     | ≤70      | 25               | 35.7% |
|                       | >70      | 45               | 64.3% |
| Stage                 | Early    | 24               | 34.3% |
|                       | Advanced | 46               | 65.7% |
| PrealloSCT treatment  | ≤3 line  | 26               | 37.1% |
|                       | >3 line  | 44               | 62.9% |
| RT                    | No       | 38               | 54.3% |
|                       | Yes      | 32               | 45.7% |
| Pre alloSCT BV        | No       | 30               | 42.9% |
|                       | Yes      | 40               | 57.1% |
| PrealloSCT CPIs       | No       | 58               | 82.9% |
|                       | Yes      | 12               | 17.1% |
| PrealloSCT disease    | CR       | 11               | 15.7% |
|                       | PR       | 18               | 25.7% |
|                       | SD/PD    | 41               | 58.6% |

|                                 |                |    |       |
|---------------------------------|----------------|----|-------|
| Conditioning regimen            | MAC            | 23 | 32.9% |
|                                 | RIC            | 47 | 67.1% |
| Stem cell source                | PB             | 62 | 88.6% |
|                                 | BM             | 7  | 10.0% |
|                                 | Umbilical cord | 1  | 1.4%  |
| ATG use                         | No             | 57 | 81.4% |
|                                 | Yes            | 13 | 18.6% |
| TBI                             | No             | 49 | 72.1% |
|                                 | Yes            | 19 | 27.9% |
| Acute GVHD                      | N/A            | 1  | 1.4%  |
|                                 | No             | 40 | 57.1% |
|                                 | Yes            | 29 | 41.4% |
| Chronic GVHD                    | N/A            | 1  | 1.4%  |
|                                 | No             | 52 | 74.3% |
|                                 | Yes            | 17 | 24.3% |
| PostalloSCT BV                  | No             | 59 | 84.3% |
|                                 | Yes            | 11 | 15.7% |
| PostalloSCT CPIs                | No             | 62 | 88.6% |
|                                 | Yes            | 8  | 11.4% |
| PostalloSCT disease             | CR             | 27 | 50.0% |
|                                 | PR             | 13 | 24.1% |
|                                 | SD/PD          | 14 | 25.9% |
| NRM                             | No             | 41 | 58.6% |
|                                 | Yes            | 29 | 41.4% |
| PostalloSCT 100th day mortality | No             | 18 | 25.7% |
|                                 | Yes            | 52 | 74.3% |

AlloSCT: Allogeneic stem cell transplant ATG: Anti Timosit Globulin BM: Bone marrow BV: Brentuximab vedotin CPIs: Checkpoint inhibitors CR: Complete Response Era 1: 2004–2010 Era 2: 2011–2021 GVHD: Graft versus host disease HCT-CI: Hematopoietic cell transplantation comorbidity index MAC: Myeloablative Conditioning N/A: Not applicable NRM: Non relapse Mortality PB: Peripheral Blood PR: Partial response RIC: Reduced-intensity conditioning RT: Radiotherapy SD/PD: Stable disease/Progressive disease TBI: Total body irradiation Tx: Transplant